Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (11): 695-699.doi: 10.3760/cma.j.cn371439-20200406-00103
• Reviews • Previous Articles Next Articles
Liu Guibin, Gao Jie, Ma Ying()
Received:
2020-04-06
Revised:
2020-08-21
Online:
2020-11-08
Published:
2021-01-05
Contact:
Ma Ying
E-mail:maying3211@163.com
Liu Guibin, Gao Jie, Ma Ying. Heart protection in the treatment of breast cancer[J]. Journal of International Oncology, 2020, 47(11): 695-699.
[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(1):7-30. DOI: 10.3322/caac.21387.
doi: 10.3322/caac.21387 pmid: 28055103 |
[2] |
Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors[J]. Epidemiology, 2016,27(1):6-13. DOI: 10.1097/ede.0000000000000394.
doi: 10.1097/EDE.0000000000000394 pmid: 26414938 |
[3] | Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association[J]. Circulation, 2017,135(10):e146-e603. DOI: 10.1161/CIR.0000000000000485. |
[4] |
Johnson CB, Davis MK, Law A, et al. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care of oncology patients[J]. Can J Cardiol, 2016,32(7):900-907. DOI: 10.1016/j.cjca.2016.04.008.
doi: 10.1016/j.cjca.2016.04.008 pmid: 27343745 |
[5] |
Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity[J]. Ann Pharmacother, 1994,28(9):1063-1072. DOI: 10.1177/106002809402800912.
doi: 10.1177/106002809402800912 pmid: 7803884 |
[6] | Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)[J]. J Clin Oncol, 2017,35(23):2647-2655. DOI: 10.1200/JCO.2016.71.4147. |
[7] |
Narayan HK, Finkelman B, French B, et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up[J]. Circulation, 2017,135(15):1397-1412. DOI: 10.1161/CIRCULATIONAHA.116.023463.
doi: 10.1161/CIRCULATIONAHA.116.023463 pmid: 28104715 |
[8] |
Mackey JR, Pieńkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial[J]. Ann Oncol, 2016,27(6):1041-1047. DOI: 10.1093/annonc/mdw098.
doi: 10.1093/annonc/mdw098 pmid: 26940688 |
[9] |
Budd GT, Barlow WE, Moore HC, et al. SWOG S0221: a phase Ⅲ trial comparing chemotherapy schedules in highrisk early-stage breast cancer[J]. J Clin Oncol, 2015,33(1):58-64. DOI: 10.1200/JCO.2014.56.3296.
doi: 10.1200/JCO.2014.56.3296 pmid: 25422488 |
[10] | Najafi S, Payandeh M, Sadeghi M. Phase Ⅱ study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer a randomised controlled clinical trial[J]. Contemp Oncol (Pozn), 2017,21(1):83-89. DOI: 10.5114/wo.2017.66661. |
[11] |
Del Mastro L, Levaggi A, Michelotti A, et al. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-Ⅲ randomized GONO-MIG5 trial[J]. Breast Cancer Res Treat, 2016,155(1):117-126. DOI: 10.1007/s10549-015-3655-1.
doi: 10.1007/s10549-015-3655-1 pmid: 26661403 |
[12] |
Gallucci G, Simeon V. Letter by Gallucci and Simeon Regarding Article, "Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy"[J]. Circulation, 2016,133(4):e362. DOI: 10.1161/CIRCULATIONAHA.115.017890.
doi: 10.1161/CIRCULATIONAHA.115.017890 pmid: 26811279 |
[13] |
Narayan HK, French B, Khan AM, et al. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction[J]. JACC Cardiovasc Imaging, 2016,9(10):1131-1141. DOI: 10.1016/j.jcmg.2015.11.024.
pmid: 27085442 |
[14] |
Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials[J]. Indian J Pharmacol, 2016,48(5):490-497. DOI: 10.4103/0253-7613.190719.
doi: 10.4103/0253-7613.190719 pmid: 27721532 |
[15] |
Tapio S. Pathology and biology of radiation-induced cardiac disease[J]. J Radiat Res, 2016,57(5):439-448. DOI: 10.1093/jrr/rrw064.
doi: 10.1093/jrr/rrw064 pmid: 27422929 |
[16] |
Saiki H, Petersen IA, Scott CG, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer[J]. Circulation, 2017,135(15):1388-1396. DOI: 10.1161/CIRCULATIONAHA.116.025434.
doi: 10.1161/CIRCULATIONAHA.116.025434 pmid: 28132957 |
[17] |
van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]. J Clin Oncol, 2017,35(11):1171-1178. DOI: 10.1200/JCO.2016.69.8480.
doi: 10.1200/JCO.2016.69.8480 pmid: 28095159 |
[18] |
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2017,35(8):893-911. DOI: 10.1200/JCO.2016.70.5400.
doi: 10.1200/JCO.2016.70.5400 pmid: 27918725 |
[19] |
van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk[J]. JAMA Intern Med, 2015,175(6):1007-1017. DOI: 10.1001/jamainternmed.2015.1180.
doi: 10.1001/jamainternmed.2015.1180 pmid: 25915855 |
[20] |
Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children[J]. Pharmacogenomics, 2015,16(10):1065-1076. DOI: 10.2217/pgs.15.61.
doi: 10.2217/pgs.15.61 pmid: 26230641 |
[21] |
Schneider BP, Shen F, Gardner L, et al. Genome-wide association study for anthracycline-induced congestive heart failure[J]. Clin Cancer Res, 2017,23(1):43-51. DOI: 10.1158/1078-0432.CCR-16-0908.
doi: 10.1158/1078-0432.CCR-16-0908 pmid: 27993963 |
[22] |
Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracyclineinduced cardiotoxicity in childhood cancer[J]. Nat Genet, 2015,47(9):1079-1084. DOI: 10.1038/ng.3374.
doi: 10.1038/ng.3374 pmid: 26237429 |
[23] | Burocchi S, Gori M, Cioffi G, et al. Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction[J]. Eur Heart J Cardiovasc Imaging, 2019,jez298. DOI: 10.1093/ehjci/jez298. |
[24] |
Hall TS, von Lueder TG, Zannad F, et al. Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction[J]. Int J Cardiol, 2018,272:260-266. DOI: 10.1016/j.ijcard.2018.07.137.
doi: 10.1016/j.ijcard.2018.07.137 pmid: 30144995 |
[25] |
Ozaydin M, Yucel H, Kocyigit S, et al. Nebivolol versus carvedilol or metoprolol in patients presenting with acute myocardial infarction complicated by left ventricular dysfunction[J]. Med Princ Pract, 2016,25(4):316-22. DOI: 10.1159/000446184.
doi: 10.1159/000446184 pmid: 27164841 |
[26] |
Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol, 2016,68(13):1476-1488. DOI: 10.1016/j.jacc.2016.05.011.
pmid: 27216111 |
[27] |
Krop IE, Modi S, Lorusso PM, et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer[J]. Breast Cancer Res, 2016,18(1):34. DOI: 10.1186/s13058-016-0691-7.
doi: 10.1186/s13058-016-0691-7 pmid: 26979312 |
[28] | Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines[J]. Cardiol Young, 2015,25 Suppl 2: 107-116. DOI: 10.1017/S1047951115000906. |
[29] |
Biener M, Giannitsis E, Kuhner M, et al. Prognostic value of high-sensitivity cardiac troponin T compared to riskscores in stable cardiovascular disease[J]. Am J Med, 2017,130(5):572-582. DOI: 10.1016/j.amjmed.2016.11.028.
doi: 10.1016/j.amjmed.2016.11.028 pmid: 28011313 |
[30] |
Todorova VK, Makhoul I, Siegel ER, et al. Biomarkers for presymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients[J]. PLoS One, 2016,11(8):e0160224. DOI: 10.1371/journal.pone.0160224.
doi: 10.1371/journal.pone.0160224 pmid: 27490685 |
[31] |
Elghazawy H, Venkatesulu BP, Verma V, et al. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving anthracyclines ± trastuzumab: a meta-analysis of clinical studies[J]. Crit Rev Oncol Hematol, 2020,153:103006. DOI: 10.1016/j.critrevonc.2020.103006.
doi: 10.1016/j.critrevonc.2020.103006 pmid: 32777728 |
[32] |
Kollárová-Brázdová P, Jirkovská A, Karabanovich G, et al. Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase Ⅱβ interaction as a prerequisite for effective protection against anthracycline cardiotoxicity[J]. J Pharmacol Exp Ther, 2020,373(3):402-415. DOI: 10.1124/jpet.119.264580.
pmid: 32253261 |
[33] |
McGowan JV, Chung R, Maulik A, et al. Anthracycline chemothe-rapy and cardiotoxicity[J]. Cardiovasc Drugs Ther, 2017,31(1):63-75. DOI: 10.1007/s10557-016-6711-0.
doi: 10.1007/s10557-016-6711-0 pmid: 28185035 |
[34] |
Knapper JT, Ghasemzadeh N, Khayata M, et al. Time to change our focus: defining, promoting, and impacting cardiovascular population health[J]. J Am Coll Cardiol, 2015,66(8):960-971. DOI: 10.1016/j.jacc.2015.07.008.
pmid: 26293767 |
[35] |
Shin WK, Song S, Hwang E, et al. Development of a FFQ for breast cancer survivors in Korea[J]. Br J Nutr, 2016: 1-6. DOI: 10.1017/S000711451600372X.
doi: 10.1017/S0007114520004961 pmid: 33298231 |
[1] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer: present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting. Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[11] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[12] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[13] | Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[14] | Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[15] | Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||